Provoked Craving Assessment

• assess the incidence and severity of adverse events [ Time Frame: from the start of the smoking abstinence sequestration period and until 5 days following last administration of the investigational product ] [ Designated as safety issue: Yes ]
  To assess the incidence and severity of adverse events
• average score [ Time Frame: during Visit 2, 5 minutes post dosing ] [ Designated as safety issue: No ]
  VAS Craving Assessment at 1, 3, 7 and 10 minutes post dosing

Evaluation of the ability of a nicotine mini lozenge to provide early relief of craving for a cigarette in smokers

• Smoking Dependence
• Smoking

• Drug: oral nicotine
  oral nicotine replacement product
• Drug: Placebo
  no active

• Active Comparator: Nicotine Polacrilex mint mini lozenge
  Intervention: Drug: oral nicotine
• Placebo Comparator: placebo
  mint mini lozenge with no active
  Intervention: Drug: Placebo

Inclusion Criteria:

• Current cigarette smokers who have smoked regularly, and smoke more than 20 cigarettes per day on a regular basis for at least a year;
• Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history.

Exclusion Criteria:

• Any disease that may interfere with the absorption, metabolism or excretion of the study product.
• A medical condition that might jeopardise the safety of the subject or the validity of the study results. For example, recent myocardial infarction or cerebrovascular incident (within 12 weeks of the screening visit), phenylketonuria, unstable or worsening angina pectoris, Prinzmetals angina or severe cardiac arrhythmia